# US 2025/0074889 A1 · Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0074889 A1
- Document ID: US20250074889A1
- Status: Published application
- Kind: A1
- Application number: 18/727,013
- Filed: 2023-01-13
- Published: 2025-03-06
- Earliest claimed: 2022-01-14
- Assignees: Daewoong Pharmaceutical Co., Ltd.
- Applicants: Daewoong Pharmaceutical Co., Ltd.
- Inventors: Youngku Kang; Inyoung Lee; Bora Yoo; Ji Duck Kim; Youngwoo Choi; Sujin Ha; Ahreum Kwon; Joon Seok Park
- Web page: https://patentgrep.com/patent/US20250074889A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/415: 1,2-Diazoles
- A61K 31/4164: 1,3-Diazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07C 233/44: having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
- C07C 237/20: the carbon skeleton containing six-membered aromatic rings
- C07D 213/16: containing only one pyridine ring
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/82: in position 3
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A compound represented by Chemical Formula 1 or 2 of the present invention, or a pharmaceutically acceptable salt thereof can be used favorably for preventing or treating cancer or tumors.

## Claims

### Claim 1

A compound represented by the following Chemical Formula 1 or 2, or a pharmaceutically acceptable salt thereof:
in Chemical Formulas 1 and 2,
L1 is a single bond, a C1-6 alkylene, a C2-4 alkenylene, or a C2-4 alkynylene,
R1 is phenyl, or a 5- or 6-membered heterocycle containing 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S,
the R1 is unsubstituted or substituted with halogen, a C1-4 alkyl, a C1-4 thioalkyl, a C1-4 haloalkyl, a C1-4 alkoxy, a C1-4 thioalkoxy, a C1-4 haloalkoxy, a C2-4 alkenyl, a C2-4 alkynyl, a C3-6 cycloalkyl, amino, nitro, cyano, a (C1-4 alkyl)amino, or a di(C1-4 alkyl)amino,
R2 is —N(R9)—L2-R5,
L2 is a single bond, a C1-6 alkylene, a C2-4 alkenylene, or a C2-4 alkynylene,
R5 is a C3-7 cycloalkyl, phenyl, or a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S,
the R5 is unsubstituted or substituted with 1 to 3 substituents each independently selected from the group consisting of hydroxy, halogen, a C1-4 alkyl, a C1-4 alkoxy, a C1-4 haloalkyl, a C1-4 haloalkoxy, a C1-4 thioalkyl, and a C3-6 cycloalkyl,
each R6 is independently hydrogen, halogen, a C1-6 alkyl, a C1-6 haloalkyl, a C1-6 alkoxy, or a C3-7 cycloalkyl,
R9 is hydrogen, halogen, a C1-4 alkyl, a C1-4 alkoxy, a C1-4 haloalkyl, a C1-4 haloalkoxy, or a C3-6 cycloalkyl,
each R3 is independently hydrogen, halogen, a C1-6 alkyl, a C1-6 haloalkyl, or a C1-4 alkoxy,
each R4 is independently hydrogen, a C1-4 alkyl, —CH2N(R7)2, or a 5- or 6-membered heteroaliphatic ring containing one or two N which is substituted with R7,
each R7 is independently hydrogen, or a C1-4 alkyl,
X is CR8, or N,
R8 is hydrogen, or halogen, and
Y is CO, CS, or SO2.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
L1 is a single bond, or —CH═CH—.

### Claim 3 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
R1 is phenyl, pyridinyl, pyrimidinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyrrolidinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl,
the R1 is unsubstituted or substituted with halogen, a C1-4 alkyl, a C1-4 thioalkyl, a C1-4 haloalkyl, a C1-4 alkoxy, a C1-4 haloalkoxy, amino, nitro, cyano, a (C1-4 alkyl)amino, or a di(C1-4 alkyl)amino.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
L2 is a single bond, methylene, or ethylene.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
R5 is cyclopentyl, cyclohexyl, phenyl, pyridinyl, pyrimidinyl, or thiazolyl,
the R5 is unsubstituted or substituted with 1 to 3 substituents each independently selected from the group consisting of hydroxy, halogen, a C1-4 alkyl, a C1-4 alkoxy, a C1-4 haloalkyl, a C1-4 haloalkoxy, a C1-4 thioalkyl, and a C3-6 cycloalkyl.

### Claim 6 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
each R6 is independently hydrogen, fluoro, chloro, difluoromethyl, or trifluoromethyl.

### Claim 7 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
R9 is hydrogen.

### Claim 8 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
each R3 is independently hydrogen, or methoxy.

### Claim 9 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
R4 is all hydrogen, or
one of R4 is hydrogen, and the other is —CH2N(R7)2, or a 5- or 6-membered heteroaliphatic ring containing one or two N which is substituted with R7.

### Claim 10 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
X is CH, CF, or N.

### Claim 11 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound is a compound represented by the following Chemical Formula 3:
in Chemical Formula 3,
X is CH, CF, or N,
A is benzene, pyridine, pyrimidine, imidazole, pyrazole, triazole, tetrazole, or oxadiazole,
R′ is hydrogen, halogen, a C1-4 alkyl, or a C1-4 alkoxy,
L1 is a single bond, a C1-6 alkylene, or a C2-4 alkenylene,
B is benzene, pyridine, pyrimidine, thiazolyl, cyclopentyl, or cyclohexyl,
each R″ is independently hydrogen, hydroxy, halogen, cyano, a C1-4 alkyl, a C1-4 haloalkyl, a C1-4 alkoxy, a C1-4 thioalkoxy, a C1-4 haloalkoxy, a C2-4 alkenyl, a C2-4 alkynyl, or a C3-6 cycloalkyl,
n″ is an integer of 1 to 3,
L2 is a single bond, or a C1-6 alkylene,
R′″ is hydrogen, or —CH2—N(CH3)2, and
R3 is hydrogen or a C1-4 alkoxy.

### Claim 12 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound is a compound represented by the following Chemical Formula 4:
in Chemical Formula 4,
X is CH, CF, or N,
A is benzene, pyridine, pyrimidine, imidazole, pyrazole, triazole, tetrazole, or oxadiazole,
R′ is hydrogen, halogen, a C1-4 alkyl, or a C1-4 alkoxy,
L1 is a single bond, a C1-6 alkylene, or a C2-4 alkenylene,
each R6 is independently hydrogen, halogen, a C1-6 alkyl, a C1-6 haloalkyl, a C1-6 alkoxy, or a C3-7 cycloalkyl,
R3 is hydrogen, or a C1-4 alkoxy, and
R′″ is hydrogen, or —CH2—N(CH3)2.

### Claim 13 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound is any one selected from the group consisting of:
1) N-(6-(cyclohexylamino)-[1,1′-biphenyl]-3-yl)acrylamide,
2) N-(4-(cyclohexylamino)-3-(pyridin-2-yl)phenyl)acrylamide,
3) N-(3-(pyridin-2-yl)-4-((cis-4-(trifluoromethyl)cyclohexyl)amino)phenyl)acrylamide,
4) N-(3-(pyridin-2-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
5) N-(2-methoxy-5-(pyridin-2-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
6) N-(3-(1-methyl-1H-imidazol-4-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
7) N-(4-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-(pyridin-2-yl)phenyl)acrylamide,
8) N-(4-((4,5-dichloropyridin-2-yl)amino)-3-(pyridin-2-yl)phenyl)acrylamide,
9) N-(4-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
10) N-(4-((4,5-dichloropyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
11) N-(6-((4-fluorobenzyl)amino)-[1,1′-biphenyl]-3-yl)acrylamide,
12) N-(4-((4-fluorobenzyl)amino)-3-(pyridin-2-yl)phenyl)acrylamide,
13) N-(3-(5-chloropyridin-2-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
14) N-(4-(pyridin-2-yl)-3-((4-(trifluoromethyl)phenyl)amino)phenyl)acrylamide,
15) N-(3-(pyrimidin-4-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
16) N-(4-((4,5-dichloropyridin-2-yl)amino)-3-(pyrimidin-4-yl)phenyl)acrylamide,
17) N-(3-(pyridin-4-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
18) N-(4-((4,5-dichloropyridin-2-yl)amino)-3-(pyridin-4-yl)phenyl)acrylamide,
19) N-(4-(5-chloro-4-fluoro-1H-indol-1-yl)-3-(pyridin-2-yl)phenyl)acrylamide,
20) N-(4-((5-cyclopropylpyridin-2-yl)amino)-3-(pyridin-2-yl)phenyl)acrylamide,
21) N-(4-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-(pyridin-2-yl)phenyl)acrylamide,
22) N-(6-(((1r,4r)-4-hydroxycyclohexyl)amino)-5-phenylpyridin-3-yl)acrylamide,
23) (E)-N-(3-(4-fluorostyryl)-4-((2-(thiazol-2-yl)ethyl)amino)phenyl)acrylamide,
24) (E)-N-(3-(4-fluorostyryl)-4-((2-(thiazol-2-yl)ethyl)amino)phenyl)ethanesulfonamide,
25) N-(4-(cyclohexylamino)-3-(pyridin-3-yl)phenyl)acrylamide,
26) N-(4-(cyclopentylamino)-3-(pyridin-2-yl)phenyl)acrylamide,
27) (E)-N-(5-(4-fluorostyryl)-6-((2-(thiazol-2-yl)ethyl)amino)pyridin-3-yl)acrylamide,
28) (E)-N-(5-(4-fluorostyryl)-6-((2-(thiazol-2-yl)ethyl)amino)pyridin-3-yl)ethanesulfonamide,
29) N-(3-fluoro-5-(pyridin-2-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
30) N-(4-((5-chloro-4-cyclopropylpyridin-2-yl)amino)-3-(pyridin-2-yl)phenyl)acrylamide,
31) N-(3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
32) (E)-4-(dimethylamino)-N-(3-(1-methyl-1H-pyrazol-3-yl)-4-((4-(trifluoromethyl)pyridin-2-yl)amino)phenyl)-2-butenamide,
33) N-(4-((5-isopropylpyridin-2-yl)amino)-3-(pyridin-2-yl)phenyl)acrylamide,
34) N-(4-((5-ethynylpyridin-2-yl)amino)-3-(1-methyl-1H-pyrazol-3-yl)phenyl)acrylamide,
35) N-(3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)phenyl)acrylamide,
36) N-(4-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
37) N-(4-((4-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-(1-methyl-1H-pyrazol-3-yl)phenyl)acrylamide,
38) N-(3-fluoro-5-(1-methyl-1H-imidazol-4-yl)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
39) N-(2′-((5-(trifluoromethyl)pyridin-2-yl)amino)-[2,3′-bipyridin]-5′-yl)acrylamide,
40) N-(4-((3-fluoro-4-(trifluoromethyl)phenyl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
41) N-(5-(1-methyl-1H-imidazol-4-yl)-6-((4-(trifluoromethyl)phenyl)amino)pyridin-3-yl)acrylamide,
42) N-(3-(1-methyl-1H-pyrazol-3-yl)-4-((4-(trifluoromethyl)phenyl)amino)phenyl)acrylamide,
43) N-(4-((3-chloro-4-(trifluoromethyl)phenyl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
44) N-(4-((2,3-difluoro-4-(trifluoromethyl)phenyl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
45) N-(3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethoxy)phenyl)amino)phenyl)acrylamide,
46) N-(4-((3,5-difluoro-4-(trifluoromethyl)phenyl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
47) N-(4-((4-chlorophenyl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
48) N-(4-((5-bromo-6-methylpyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
49) N-(4-((5-chloro-6-methylpyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
50) N-(4-((5-chloropyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
51) N-(4-((5-bromo-4-chloropyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
52) N-(4-((5-bromopyridin-2-yl)amino)-3-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide,
53) N-(4-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-(1-methyl-1H-pyrazol-3-yl)phenyl)acrylamide,
54) N-(3-(1-methyl-1H-pyrazol-3-yl)-4-((4-(trifluoromethyl)pyridin-2-yl)amino)phenyl)acrylamide,
55) N-(4-((4,5-dichloropyridin-2-yl)amino)-3-(1-methyl-1H-pyrazol-3-yl)phenyl)acrylamide, and
56) N-(4-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-(1-methyl-1H-pyrazol-3-yl)phenyl)acrylamide.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A method for preventing or treating cancer or tumors in a subject in need thereof, comprising administering the subject the compound of claim 1, or a pharmaceutically acceptable salt thereof as an active ingredient.
